Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Other Accumulated Expenses (2016 - 2025)

Ironwood Pharmaceuticals' Other Accumulated Expenses history spans 16 years, with the latest figure at $9.4 million for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 112.92% year-over-year to $9.4 million; the TTM value through Dec 2025 reached $9.4 million, up 112.92%, while the annual FY2025 figure was $9.4 million, 112.92% up from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $9.4 million at Ironwood Pharmaceuticals, up from $7.5 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $14.3 million in Q3 2023 and bottomed at $438000.0 in Q2 2021.
  • The 5-year median for Other Accumulated Expenses is $5.7 million (2023), against an average of $6.1 million.
  • The largest annual shift saw Other Accumulated Expenses tumbled 83.16% in 2021 before it soared 964.61% in 2022.
  • A 5-year view of Other Accumulated Expenses shows it stood at $3.4 million in 2021, then rose by 5.53% to $3.6 million in 2022, then surged by 72.71% to $6.2 million in 2023, then dropped by 28.71% to $4.4 million in 2024, then skyrocketed by 112.92% to $9.4 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Other Accumulated Expenses are $9.4 million (Q4 2025), $7.5 million (Q3 2025), and $5.2 million (Q2 2025).